false 0001609809 0001609809 2023-08-08 2023-08-08












Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2023




(Exact name of Registrant as Specified in Its Charter)




Delaware   001-37465   27-4326290

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


200 Sidney Street - 4th Floor

Cambridge, MA

(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 945-9626

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class




Name of each exchange

on which registered

Common stock, par value $0.001 per share   MCRB   The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 2.02.

Results of Operations and Financial Condition.

On August 8, 2023, Seres Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).

The information in this Item 2.02 of this Current Report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.


Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

The following Exhibit 99.1 relates to Item 2.02 and shall be deemed to be furnished, and not filed:




99.1    Seres Therapeutics, Inc. Press Release issued August 8, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: August 8, 2023     By:  

/s/ Thomas J. DesRosier

    Name:   Thomas J. DesRosier
    Title:   Chief Legal Officer and Executive Vice President
EX-99.1 2 d541674dex991.htm EX-99.1 EX-99.1

Exhibit 99.1



Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

– VOWSTTM is the first orally administered microbiome therapeutic FDA-approved for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI (rCDI) –

– VOWST early commercial uptake encouraging with strong initial demand observed across healthcare provider specialties and rCDI patient profiles, including first recurrence –

–SER-155 Phase 1b Cohort 1 clinical data showed favorable tolerability, successful drug bacteria engraftment and a substantial reduction in pathogen domination in the gastrointestinal microbiome; Cohort 2 data readout anticipated in mid-2024

– Conference call at 8:30 a.m. ET today –

CAMBRIDGE, Mass., August 8, 2023 Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported second quarter 2023 financial results and provided business updates.

“Seres achieved a major corporate milestone during the second quarter with the FDA approval of VOWST, the first and only FDA-approved, orally administered microbiome therapeutic for the treatment of adult recurrent C. difficile infection patients, including those with first recurrence,” said Eric Shaff, President and Chief Executive Officer at Seres. “Alongside our collaborator, Nestlé Health Science, we have been executing the VOWST launch in the United States, and we are highly encouraged by the early performance. This includes the breadth of the prescriber base, use across the rCDI patient pool – including first recurrence – as well as the progress being made in payer discussions. We continue working to enable eligible individuals to gain access to this important new medicine as quickly and efficiently as possible.”

“We also made meaningful progress with our earlier-stage pipeline. Initial Phase 1b Cohort 1 data from our investigational SER-155 program support our therapeutic objective of reducing serious enteric infections, resulting bloodstream infections and GvHD in allo-HSCT patients, a medically vulnerable population. The SER-155 study continues to enroll, and we anticipate top-line results from the placebo-controlled portion of the study in mid-2024.”

FDA Approval of VOWST and Initial Commercial Uptake: In April 2023, Seres and Nestlé Health Science announced the Food and Drug Administration (FDA) approval of VOWST (fecal microbiota spores, live-brpk), formerly called SER-109, an orally administered microbiome therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). VOWST is thought to facilitate restoration of the gut microbiome.

Recurrent CDI is a serious disease that often results in hospitalization and can lead to death. There are an estimated 156,000 recurrences in the United States and at least 20,000 deaths due to C. diff infections per year.

In July 2021, Seres and Nestlé Health Science entered into an agreement to jointly commercialize VOWST in the U.S. and Canada. Nestlé Health Science is leveraging its global pharmaceutical business, including the utilization of its existing U.S. infrastructure with a 150-person gastrointestinal sales force, a payer access team, and a 20-person hospital salesforce. Seres and Nestlé Health Science are committed to helping patients who have been prescribed VOWST obtain access. See www.vowst.com for further information.

VOWST became commercially available in the U.S. in early June 2023. Encouraging and broad early demand has been observed across patients and healthcare providers during the early launch period (metrics noted below are based on data through July 27, 2023, as provided by Nestlé Health Science):



610 completed prescription enrollment forms for VOWST were received; of those 282 have already culminated in new patient starts



Prescription enrollment forms were submitted by over 480 unique healthcare providers (HCPs), with approximately 70% from gastroenterology and the remainder from other specialties; 78 HCPs have prescribed VOWST to more than one patient



Early VOWST demand was observed across the recurrent CDI patient pool, including first recurrence, which is the largest rCDI patient segment

Payer engagement continues, including with the three largest Pharmacy Benefit Managers (PBMs). The Company expects coverage policies to begin to be issued during H2 2023.

VOWST Phase 3 Development Program: The FDA approval of VOWST was supported by a robust Phase 3 development program that included the ECOSPOR III and ECOSPOR IV studies. VOWST was previously granted Breakthrough Therapy and Orphan Drug Designations by the FDA.

ECOSPOR III was a multicenter, randomized, placebo-controlled study in individuals with rCDI, the results of which were published in the New England Journal of Medicine. The study’s primary objective was to demonstrate the reduction of CDI recurrence with VOWST. In ECOSPOR III, VOWST was shown to reduce CDI recurrence at eight weeks, with approximately 88% of individuals recurrence-free at eight weeks post-treatment, compared to 60% in participants who received placebo. In addition, at six months post-treatment, 79% of the VOWST group were demonstrated to be recurrence-free, compared to 53% in the placebo group. No serious adverse events were considered related to VOWST. The most common solicited adverse reactions reported by ≥5% of VOWST recipients, and at a rate greater than that reported by placebo recipients through eight weeks were abdominal distention (31.1% VOWST versus 29.3% placebo), fatigue (22.2% VOWST versus 21.7% placebo), constipation (14.4% VOWST versus 10.9% placebo), chills (11.1% versus 7.6% placebo), and the unsolicited event of diarrhea (10.0% versus 4.3% placebo).

ECOSPOR IV was an open-label, single arm study evaluating VOWST in 263 adult participants with rCDI. Study results were published in the JAMA Network Open. The ECOSPOR IV study results contributed to the VOWST safety database and supported product approval.

SER-155 Phase 1b Cohort 1 Study Results: In May 2023, Seres announced SER-155 safety and pharmacology clinical data in allo-HSCT subjects including:



favorable tolerability profile observed, with no serious adverse events attributed to SER-155 administration patients;



bacteria in the SER-155 engrafted, populating the gastrointestinal (GI) microbiome, with a magnitude and kinetics consistent with expectations from prior clinical results from other Seres microbiome therapeutics; and



cumulative incidence of domination with ESKAPE pathogen bacterial families was rare and observed at substantially lower incidence rates than observed in a reference population of allo-HSCT patients.1

SER-155 is an investigational, orally administered, 16-strain, cultivated microbiome therapeutic designed to prevent colonization and reduce the abundance and domination of ESKAPE pathogens (e.g., from families such as Enterococcaceae, Enterobacteriaceae, Streptococcaceae, Staphylococcaceae) in the GI tract to reduce the risk of enteric driven bloodstream infections and other downstream consequences such as GvHD in patients receiving allo-HSCT. SER-155 has the potential to also impact antimicrobial resistance (AMR), including infections caused by carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant Enterococci (VRE). The development of SER-155 is supported by SER-109 Phase 3 ECOSPOR III study exploratory results showing the decolonization of gut pathogens beyond C. difficile, including bacteria carrying antibiotic resistance genes, in the GI microbiome following SER-109 administration.

The ongoing SER-155 Phase 1b study includes two cohorts, with Cohort 1 designed to assess safety and drug pharmacology, including the engraftment of drug bacteria in the gastrointestinal tract and the reduction in abundance and dominance of ESKAPE pathogens which has been associated with increased risk of blood stream infections, severe forms of GvHD, and patient survival.

Enrollment of the Cohort 2 study is ongoing, incorporating a randomized, double-blinded placebo-controlled design to further evaluate safety and engraftment, as well as clinical outcomes, and will enroll approximately 60 subjects administered either SER-155 or placebo at a 1:1 ratio. The Company anticipates obtaining Cohort 2 study data in mid-2024.

Infection Protection Research: The Company continues to conduct research to bring forward new investigational microbiome therapeutics as a novel approach for Infection Protection for medically compromised individuals, including those with cancer neutropenia, cirrhosis or solid organ transplant. Clinical and preclinical studies are evaluating the potential to reduce the abundance of targeted pathogens to decrease the potential for pathogen transmission, strengthen epithelial barriers to further reduce translocation and the frequency of bloodstream infections, and to modulate immune responses to tackle medical complications such as graft-versus-host disease (GvHD). The Company plans to announce an additional microbiome therapeutic program in H2 2023.

Ulcerative Colitis (UC) Research: The Company previously reported clinical, microbiome and metabolomic data from the SER-287 Phase 2b study and the first cohort of its SER-301 Phase 1b study. Available data for these investigational microbiome therapeutics suggest that there may be an opportunity to utilize biomarker-based patient selection and stratification for future studies. Research activities remain ongoing to inform potential further development activities.

Financial Results

Seres reported net income of $46.6 million for the second quarter of 2023, as compared with a net loss of $64.7 million for the same period in 2022. The net income in the second quarter of 2023 was primarily due to the $125 million milestone received from Nestle upon FDA approval of VOWST. Net sales of VOWST for the second quarter of 2023, the first partial quarter following launch, were $1.6 million. Following the first commercial sale of VOWST, Seres shares equally with Nestle, its collaborator, in the VOWST commercial profits and losses. Seres share of the VOWST net loss for the second quarter of 2023 was $2.1 million, which was included in the Company’s operating results within Collaboration (profit) loss sharing—related party.

Research and development expenses for the second quarter of 2023 were $46.8 million, compared with $43.9 million for the same period in 2022. The research and development expenses were primarily related to Seres’ VOWST clinical development program and manufacturing costs, as well as personnel expenses. Included in the second quarter 2023 total R&D expenses are $11.0 million of commercial manufacturing costs for VOWST. Following the approval of VOWST, R&D expenses in the Seres P&L will no longer include VOWST commercial manufacturing costs, as these costs will be capitalized and recognized on the Company’s balance sheet. The second quarter 2023 total R&D expenses also reflected a $4.5 million increase in stock-based compensation expense versus the same period in 2022, primarily due to stock options and restricted stock units (RSUs) with performance conditions that either started vesting or vested upon VOWST approval.

General and administrative expenses for the second quarter of 2023 were $28.1 million, compared with $20.3 million for the same period in 2022. General and administrative expenses were primarily related to personnel expenses, professional fees, including VOWST commercial readiness and pre-launch expenses, and facility costs. The second quarter 2023 total G&A expenses also reflected a $2.3 million increase in stock-based compensation expense versus the same period in 2022, primarily due to stock options and RSUs with performance conditions that either started vesting or vested upon VOWST approval. Additionally, G&A expenses in the second quarter of 2023 reflect $3.8 million of one-time transaction and milestone payments due to third parties as a result of the FDA approval of VOWST.

The Company remains disciplined with its cash deployment and is prioritizing 1) the successful commercial launch for VOWST, and 2) continued development of SER-155. Given the 3-year shelf life of VOWST and operational efficiencies related to the VOWST production process, the Company was able to close one of its three donor collection facilities supporting VOWST manufacturing, reducing costs without impacting the ability to meet anticipated market demand. In addition, the Company recently opened a centralized donor screening lab allowing for in-house donor medical testing, resulting in expected future cost savings. The Company remains committed to further reducing costs and plans to share additional updates in the future.

Seres ended the second quarter of 2023 with $229.5 million in cash, cash equivalents, and investments as compared with $181.3 million at the end of 2022. In May, Seres received a $125.0 million milestone payment from Nestlé Health Science associated with the FDA approval of VOWST.

In April 2023, Seres announced that it had entered into a new $250.0 million senior secured debt facility provided by funds managed by Oaktree Capital Management, L.P. The Company drew the first tranche of $110.0 million at closing, with three additional tranches available. These additional tranches include $90.0 million that will be available in two tranches of $45.0 million each based upon the achievement of certain applicable VOWST sales targets, and an additional $50.0 million will be available to the Company at Oaktree’s discretion to support potential future business development activities. Of the $110.0 million advanced by Oaktree at closing, $53.4 million retired outstanding debt, and after deducting fees and expenses, the net proceeds to the Company were $50.4 million.

Conference Call Information

Seres’ management will host a conference call today, August 8, 2023, at 8:30 a.m. ET. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference Conference ID 4844622. To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for at least 21 days.



VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).

Limitation of Use: VOWST is not indicated for treatment of CDI.



Transmissible infectious agents: Because VOWST is manufactured from human fecal matter, it may carry a risk of transmitting infectious agents. Report any infection that is suspected to have been transmitted by VOWST to Aimmune Therapeutics, Inc. at 1-833-246-2566.

Potential presence of food allergens: VOWST may contain food allergens. The potential to cause adverse reactions due to food allergens is unknown.


The most common adverse reactions (reported in ≥5% of participants) were abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%), and diarrhea (10.0%).

To report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics at 1-833-AIM-2KNO (1-833-246-2566), or the FDA at 1-800-FDA-1088, or visit www.fda.gov/MedWatch.


Do not administer antibacterials concurrently with VOWST.

Please see Full Prescribing Information and Patient Information

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. In June 2023, Seres was named one of the TIME100 Most Influential Companies. Seres’ lead program, VOWST, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com.

About SER-155

SER-155 is a consortium of bacterial species selected using Seres’ reverse translation discovery and development platform technologies. The design incorporates microbiome biomarker data from human clinical data and nonclinical human cell-based assays and in vivo disease models. The SER-155 composition aims to decrease the colonization and abundance of bacterial pathogens that can harbor antibiotic resistance and to enhance epithelial barrier integrity in the GI tract to both reduce the likelihood of pathogen translocation and decrease the incidence of bloodstream infections. Further, SER-155 is designed to modulate host immune responses to decrease GvHD.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the commercial success of VOWST, the timing and results of clinical studies, the ability for microbiome therapeutics to modulate the microbiome and treat or prevent infection, our ability to achieve sales targets and the receipt of future milestones and debt tranches, and other statements which are not historical fact.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates and develop and commercialize VOWST and any other product candidates, if approved; the unknown degree and competing factors of market acceptance for VOWST; the competition we will face; our ability to protect our intellectual property; and our ability to retain key personnel and to manage our growth. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), on May 9, 2023, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.



(unaudited, in thousands, except share and per share data)


     June 30,
    December 31,



Current assets:


Cash and cash equivalents

   $ 229,520     $ 163,030  

Short term investments

     —         18,311  

Collaboration receivable - related party

     7,559       —    


     5,340       —    

Prepaid expenses and other current assets

     8,819       13,423  







Total current assets

     251,238       194,764  

Property and equipment, net

     24,026       22,985  

Operating lease assets

     110,283       110,984  

Restricted cash

     8,185       8,185  

Restricted investments

     1,401       1,401  

Other non-current assets

     11,254       10,465  







Total assets

   $ 406,387     $ 348,784  







Liabilities and Stockholders’ Equity


Current liabilities:


Accounts payable

   $ 12,922     $ 17,440  

Accrued expenses and other current liabilities (1)

     55,878       59,840  

Operating lease liabilities

     5,470       3,601  

Short term portion of note payable, net of discount

     —         456  

Deferred income - related party

     2,817       —    

Deferred revenue - related party

     811       4,259  







Total current liabilities

     77,898       85,596  

Long term portion of note payable, net of discount

     100,742       50,591  

Operating lease liabilities, net of current portion

     106,706       107,942  

Deferred revenue, net of current portion - related party

     94,927       92,430  

Warrant liability


Other long-term liabilities

     1,532       1,442  







Total liabilities

     383,773       338,001  







Commitments and contingencies (Note 14)


Stockholders’ equity:


Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 2022

     —         —    

Common stock, $0.001 par value; 240,000,000 and 200,000,000 shares authorized at June 30, 2023 and December 31, 2022, respectively; 128,037,679 and 125,222,273 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively

     128       125  

Additional paid-in capital

     911,620       875,181  

Accumulated other comprehensive loss

     (1     (12

Accumulated deficit

     (889,133     (864,511







Total stockholders’ equity

     22,614       10,783  







Total liabilities and stockholders’ equity

   $ 406,387     $ 348,784  







Includes related party amounts of $31,372 and $34,770 at June 30, 2023 and December 31, 2022, respectively



(unaudited, in thousands, except share and per share data)


     Three Months Ended
June 30,
    Six Months Ended
June 30,
     2023     2022     2023     2022  



Collaboration revenue - related party

   $ 126,473     $ 1,216     $ 125,951     $ 2,709  













Total revenue

     126,473       1,216       125,951       2,709  

Operating expenses:


Research and development expenses

     46,792       43,935       90,761       83,584  

General and administrative expenses

     28,051       20,335       50,521       38,906  

Collaboration (profit) loss sharing - related party

     2,106       271       5,713       (705













Total operating expenses

     76,949       64,541       146,995       121,785  













Income (loss) from operations

     49,524       (63,325     (21,044     (119,076













Other income (expense):


Interest income

     1,726       395       2,758       779  

Interest expense

     (3,187     (1,501     (5,135     (2,413

Other expense

     (1,511     (304     (1,201     (649













Total other expense, net

     (2,972     (1,410     (3,578     (2,283













Net income (loss)

   $ 46,552     $ (64,735   $ (24,622   $ (121,359













Net income (loss) per share attributable to common stockholders, basic

   $ 0.36     $ (0.70   $ (0.19   $ (1.32

Net income (loss) per share attributable to common stockholders, diluted

   $ 0.36     $ (0.70   $ (0.19   $ (1.32













Weighted average common shares outstanding, basic

     127,713,486       92,255,416       126,793,342       92,224,382  

Weighted average common shares outstanding, diluted

     129,844,931       92,255,416       126,793,342       92,224,382  













Other comprehensive (loss) income:


Unrealized (loss) gain on investments, net of tax of $0

     (2     (41     10       (196

Currency translation adjustment

     (1           1        













Total other comprehensive (loss) income

     (3     (41     11       (196













Comprehensive income (loss)

   $ 46,549     $ (64,776   $ (24,611   $ (121,555















Peled, J, Gomes, A, Devlin, S, et al. (2020). Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 382(9), 822–834. DOI: 10.1056/nejmoa1900623

IR and PR Contact:

Carlo Tanzi, Ph.D.



EX-101.SCH 3 mcrb-20230808.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 mcrb-20230808_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 mcrb-20230808_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g541674g0808015732284.jpg GRAPHIC begin 644 g541674g0808015732284.jpg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htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Aug. 08, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001609809
Document Type 8-K
Document Period End Date Aug. 08, 2023
Entity Registrant Name SERES THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37465
Entity Tax Identification Number 27-4326290
Entity Address, Address Line One 200 Sidney Street - 4th Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (617)
Local Phone Number 945-9626
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.001 per share
Trading Symbol MCRB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d541674d8k_htm.xml IDEA: XBRL DOCUMENT 0001609809 2023-08-08 2023-08-08 false 0001609809 8-K 2023-08-08 SERES THERAPEUTICS, INC. DE 001-37465 27-4326290 200 Sidney Street - 4th Floor Cambridge MA 02139 (617) 945-9626 false false false false Common stock, par value $0.001 per share MCRB NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d541674d8k.htm d541674dex991.htm mcrb-20230808.xsd mcrb-20230808_lab.xml mcrb-20230808_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d541674d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "d541674d8k.htm" ] }, "labelLink": { "local": [ "mcrb-20230808_lab.xml" ] }, "presentationLink": { "local": [ "mcrb-20230808_pre.xml" ] }, "schema": { "local": [ "mcrb-20230808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mcrb", "nsuri": "http://serestherapeutics.com/20230808", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d541674d8k.htm", "contextRef": "duration_2023-08-08_to_2023-08-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d541674d8k.htm", "contextRef": "duration_2023-08-08_to_2023-08-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://serestherapeutics.com//20230808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-205557-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-205557-xbrl.zip M4$L#!!0 ( *TX"%>\>H\M-P\ &5C . 9#4T,38W-&0X:RYH=&WM M'&MSVKCV^\[L?]#0NSMD)H -Y %YW$D);=FF) /T[L[]TA&V &V-Y4IV O?7 MWW-D&PR8 F0=IO.[,9&1]+1>9\CR>?_'@T=HZN:%[!?BEAEP5[AN,)P /SP\Y/7PV,'V90%[% H!U!, MB M52E :PS(E2@7S9-'UA!!3#J,EL&: .O"BME?;ULW4W _'7X*6O E=55/R"'U M06IPI*.<4YDCFA)4S.'UOJ'!6QU9Z3S0CXN! V M1J#+I07E/*,%GE$;__K<=]CE:>[C>2%\A-^&S*<$1\BQ;P&_O\C4A.LSU\]U M0$0SQ K?+C(^&_D%/2(I8+]"-"@AY+PK[/'ENK5D+DV_.>_>@X.C?!A)106W/Q?J<'RD[;J;2D@)9M+;AV(%)NCPOS*XG6OW, MBO6[$H$,7[4"52-R:^ZM0>ZX&]/,F[QR&W_H<2:)1H&EJG>M\7&68?.=$>O4 M\3W@J+ GKZ#9TK^F/KN[F\+E*:."+ M^!?)^X/H)QS.BP=#HYD;,-T*7MJ;#.$+KYIX[0K?%T/]2U=(0#W^Q?1&1 F' MV^2-H?]E+G]_ UPZ.R]XRR8JK9ZH^.2)$L.681"RN #2 ];D%/\?JYJGD_<> M'7)G7.WP(5.DR1Y(2PRI>Z;;'D*\N\*QSU+8\[G9Z-2O2;MSU:FWEZ-C[ F= M=KWVN=7H-.IMDZDCDK$*LT*E4RCY\DF7D#P&:%\RS4TJ+YV^+J MU]32Z6)B(Y'&,'-?4O7NMO5I>9!P+:P 8X1$H+*^(]9!T*P'?I6$G4C"5G07 MK$NKWNR05OWNMM5Y>5MR%T@54-'D$18] ?H>X M!9+['/K71]: NGU&KBR?0+-9*967X[DWSF)$@^BTF">D3[+Q.Z,0T4"22M@] M0!*IFYE]4%UM$.YT6%0/HZ5-+0,)L[B+#&1^51L&&$+W@4W'8\"(N9G+JZ ? M %JGAP1[O1J1?1B18GD;HK9<A96.7TJZW(/SI?*BWKN[J MGSN-6ON0-)JU?$JF]PSK8&R#$MGZB((50 *$NAD M-H >30M+Y=\PH_?MN=9[ M)GUN42>B;KC@5,AHG.(&X\0XIW>9'Q#^%^$N8Q"/]EFN*QG]BA5,2.JK]%Z MA*Q-.%.S;G9>DI F,B-.52U(9&XM(!. (;#9G9&=A/9"\^-&J^%:0H)OU-:I M[8/#JHG ]>6X)NQG.3\L>V)YPF>>%/%RL&(^1 M9Q?:>;HEY7RJG]Y*_IO5^HQ9A<#-&O(WQ/+*YCK=V"B(,'> ',0-/&E[#D)? M^#+B_K)LJHGAD"OU/7 %31D)M?4G9DBCU2;UH>>(,9,OSI)92TJ:(C_EC#9] M\#\,^7[8$%*C^+P8\LC88[]8[UXV$UP1"%S9MF1*17]N(!VR,6G[DC&?Y$C9'Y!WCA!R1?UD(VW=)T5J\'@K.^+!W9@>-3KL2F[W M%V+HPU4%BFAN'17H*^F4C"F&IQY,@,MRC#F$C9@4^O\<*$#@GI@Z^[Y0E M"ZPER-N#!;:D.- -2]E;L1S3,MKO;TZ+YLF9 CHXS!L(EQ%7QV2'&#,[ ;I@ M EDT!3$%L5FN]VAFK@#N23*=/39/#E:=@YG.=2. (7>([!.SO4KY*% 65_UMAKU/"G E&)VWA4CTF6.>$"N82,R MDYSF/I(>=U#/N0*E]YEK S=]010?!HY/728"Y8R) JU2O;'N&7407:!#F"Q$ MVWAR6J /8!Q)J#N.VWH0KHL'[(=U.HY9J*HNE9'C)V<36\T6)BG"-&U8S$_F M\I?UO.^\0XW2@=_.4EW.,EOXI^0^L P3^\"-,C?U[&IJ5PBG2X%=/@@-4KER M4BZ?+9K+5?YW/L,FLQPESS:I\,I<1/8 28(0+[$-W@I 2,K%HTA"YW:? M<=,Y:YZ0VKL6*9:,/ !ND@6_BNU:8ML&ZVH!P=W^)S!-8)^2H9W%<[_Z.!=Z2GG;ZVT>@?Z# MA!>(DK,25%EI>LMH! M]UD.Y8&!?7B0=).]N5WLAG7PXEEXP-,:$,NA2NVK^OQ4(KXTQ21%Y3WO2E*X M;(^' )=5>]OZ7&#,[CL*>PQA2%WLYHHI@Z5=#IF.BO'UM&-BW/QNMW8R ME_4E5%JQ)1QW>Z][U<).>TN]=DN21N\1\<']Q519Y L;"0.0-*TS(&FNT'E* MH)B& AI%VQ7X60.N*.93SGDD1WNI@M%C 72XS!93@>/K2K^99P>P+!WF]4><2,] +'T=%B;'4]?61(@HN@X!8X%C)U M2 ).U(WJ6=K\Z_WP"%==UH/XH!=(EZL!=* 86PQXE_ND4LF;:.AU!%$+I$3@ MZ-HG#*:WS6<$.:UVH>]M:_&=)=[,<#$-\X]DYH"1]#C#9 4:@0^XRB 2!I':\R!YWF!VM3;,?W*L^3]>,\0Z10708RDZ2H$G@F)R'DYL(#^#EB0JZ?V/(K5G*B,-IESOA5'IR MZA,5(G4(ZY'1RGAR8=,+!/ " 4HP XN0R-Y7S8<(@U M .;I^XULI$4;SUY :@%T!"&&N55X[=&:14(%D*V'6"Q(4T)23I^[._+JG(RS M2MXP?USG-'5!^GPNFL+0-T7ZK5[ (67M@\GT>[&%T\-(,U8?O AZ&C054\N( MM EMPM0@ $"73=W'H09"8ZAM7_41#2SN>L-D.QJZQHX)QLK1KDGT8(=2$[^M ML[^Q9&LE;*R4]KR_L?;>1*SK*2<0MUM#3DE (HG=:9$X]6AJ_BFU_*4EO_7W M@:Z9LB3WPMN$L3!,I2]%R18Y&Q\)Q9849!+-$#BBF@%SBWN^F;/H*U+)@99J M5UP(ZZJ4A%_GLX_*YO%)V6:C2L7,#_PA;B(O21'N=!C>F@W#4[(,,(UT*5E_ M%A::1GFG'*P)^)79EEPRZS,9C&W$AG PB*Y1Z" M'PHE=O2-FH.DQDTB 7RNP+44]WVZALC_EMW;[HN'<%^T(! M0&\67ZS8N=I0W=74 6(<^%9D3_R!'*0EE \ M_$S#]R!!/YR@X"&,'8I**JM>V;0QF_3IJ!WRJ3;@K$=N6)\ZY%9?Z)91]3&^ MYOT?^$VGD_H+YNOF'^>%\.O^^MO_E_\'4$L#!!0 ( *TX"%>]V&?$#S M %.@ 0 1 9#4T,38W-&1E>#DY,2YH=&WM?6ESXLBRZ'='^#]4>+HG[ A! M([';;L?#F.GF7&_7N&?N>2_>!P$%:%I(C"3LYOSZFYE5I87%AC;8T-999@Q( MM63EOM7IU_NKR[/3KXW:Q=G^WNE]\_ZR<=;XGTRUFM5//XF/\/TG^0 [/;^Y M^#<[_U*_N;RY^WSPU]?F?>. M>[_?=GX?&!;#L\,N-4?!,?7KCY$W#O[/2B^:=Z^-'J!H/C2K9H.0?,M*V^ P/P7G! T]RJQX:FU[><3.". MCG.CX(3)SVTW"-RA^*KG.D'&M_[#C_7H<\\<6O;D^-X:G)V>GS5^#*RV%3#<,3O]='YV^NGV++: V.@&C#ZUGIGE')S] M[K3]T0F. AM?M(\Y[R&@X(WFU1?6NJM_/N@7"WJI7.CG*O!?O5C.&T:ED/U[ MU,=-W'\^N+SY/W ^X9X[X.+ Z/KOC(]<+ M?-;B'=?ILO\>FQX\S8R<^6%T8YWSL ^+X M/OLVZIH!?*%.80'\-K.KYMGOO^G%W G[\^:OUOUIZ]L<#"@7/YZP!^[!CDT[ M0TA[#"LZ.+N_.OT$;YPQRV?!@+.>Y?D!.S@[(^+6L8QYT.QT_U+.M:O9[5L6S.+*?'._2-X,A#$M3J$$#5K]HLD,/_GG$)+A./S6?.JS2 MYL^*<=,#,'?[2" ?,#SX6_X30"?*S+AXB( M;MOG'@"5F7 T@(8#;MK!H&-ZG(T$CGK,'W$<.;"X0%X$ 1N9\-D)]O?@L1Y MV-=@Z(X][N*$ @5BQS$%K_D4NR%P"?1Z KG$XEJ-NXQ>+"KLNAV8/F=ZF]7= M 1 WTUD'6#SB/@-"-??W_('["'#KF0^ ZFU L<"U :?;EFT%$XWYXTX'Z+HW MAN>]<9\I](*#Z7MF3^ 70M.$1]M^@"@(8P.9C$,\!1@/W#YW6-<%*C+5UTAD M?1//TX)-^@'\9,=HZT0MV:"5PI!FUQT'A.0="\:$5<,HSX)E:'4SP,(*"B(" M3"@0W^ 0)0+57:!C@5)P$C8S U8YSN>8F1UF6>,>SJ!K3EZ1.E$@U&M7YW?- MBR\-C5V9OI_56&W<'_L!<7)DYO0O(1DKFI *^"6N4H=5?ILC4C36=#K9TT_? MSMCAM>EWS7^.V57][OQ( WRQX4"1RN:S4Q^9PZSQ ]X+K ?.;G!V@"(0 M&1U'EHFSJ=D@2/ ]!A(&CL2VS38>BNMI<)!^8/_.31@"&-%7DB:LU;%H&>R1 MLX$)([SU4PF'6+! 6:"8"4ERH*&WDB; P@#Q^!"W"[WA6&_;:!JZO ML3&P?BD0\?>XP&,CU[45AWE>XID^+!D9E2]G
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